Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
BMJ Case Rep ; 17(1)2024 Jan 24.
Artículo en Inglés | MEDLINE | ID: mdl-38272515

RESUMEN

Myocardial contusion should be suspected in a selected patient group with blunt thoracic trauma, who have elevated troponin, ECG changes and/or haemodynamical instability. Echocardiography is useful for direct visualisation of possible complications. In stable conditions, MRI allows for good visualisation of the heart and can confirm a suspected myocardial contusion as well as demonstrate the extent of myocardial damage. Based on the present literature, the authors developed a diagram for the diagnostic approach of a patient with suspected myocardial contusion.


Asunto(s)
Contusiones , Lesiones Cardíacas , Contusiones Miocárdicas , Traumatismos Torácicos , Heridas no Penetrantes , Humanos , Lesiones Cardíacas/etiología , Lesiones Cardíacas/complicaciones , Contusiones Miocárdicas/diagnóstico por imagen , Contusiones Miocárdicas/complicaciones , Troponina , Ecocardiografía , Heridas no Penetrantes/complicaciones , Heridas no Penetrantes/diagnóstico por imagen , Traumatismos Torácicos/complicaciones , Traumatismos Torácicos/diagnóstico por imagen , Contusiones/diagnóstico por imagen , Contusiones/etiología , Electrocardiografía
2.
Eur Heart J Case Rep ; 5(10): ytab333, 2021 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-34703979

RESUMEN

BACKGROUND: Cardiotoxicity presenting as cardiomyopathy is a common side effect in cancer treatment especially with anthracyclines. The role of genetic predisposition is still being investigated. CASE SUMMARY: Four unrelated patients with a familial burden for cardiac disease, who developed cardiomyopathy after anthracycline treatment are presented. Case 1 received chemotherapy for breast cancer and developed a dilated left ventricle just after treatment. Her father had died unexpectedly while being screened for heart transplant. Case 2 was known with a family history of sudden cardiac death prior to her breast cancer diagnosis. She received anthracycline-containing chemotherapy treatment twice in 5 years due to recurrence of breast cancer. During that period, two brothers developed a cardiomyopathy. Eighteen years later, a genetic predisposition for cardiomyopathy was ascertained and at screening an asymptomatic non-ischaemic cardiomyopathy was established. Case 3 was diagnosed with a dilated cardiomyopathy 1 year after chemotherapy treatment for breast cancer. Her mother had developed a dilated cardiomyopathy several years before. Case 4 received chemotherapy treatment for Non-Hodgkin's lymphoma and developed dilated cardiomyopathy 1 year later. His brother died from congestive heart failure which he developed after chemotherapy for Non-Hodgkin's lymphoma and a grandmother had died suddenly during child delivery. In all four cases, genetic screening showed (likely) pathogenic variants in cardiomyopathy-associated genes. DISCUSSION: Current guidelines recommend cardiac evaluation in cancer patients receiving chemotherapy based on the presence of cardiovascular risk factors at the start of treatment. This series emphasizes the importance of including a thorough family history in this process.

3.
Int J Cardiol ; 206: 21-6, 2016 Mar 01.
Artículo en Inglés | MEDLINE | ID: mdl-26773766

RESUMEN

The Fontan procedure has been used since 1971 as a palliative treatment for various (functionally) univentricular hearts. The systemic venous blood flows passively to the pulmonary arteries, without passing through a functional ventricle. This results in chronic systemic venous congestion, which may lead to liver fibrosis, cirrhosis and hepatocellular carcinoma. This review discusses possible screening modalities for liver fibrosis and cirrhosis in the Fontan population and proposes a screening protocol. We suggest starting screening for progression of fibrosis and cirrhosis in collaboration with the hepatologist circa 10 years after Fontan completion. The screening programme will consist of a yearly evaluation of liver laboratory tests in conjunction with imaging of the liver with ultrasound or MRI every two years. In case of liver fibrosis or cirrhosis, (reversible) causes should be ruled out (e.g. obstruction in the Fontan circuit). In case of severe fibrosis or cirrhosis, other complications of portal hypertension should be evaluated and screening for hepatocellular carcinoma is required on a regular (6-12 months) basis. As regards hepatocellular carcinoma, treatment should be discussed in a multidisciplinary team, before deciding a treatment modality.


Asunto(s)
Carcinoma Hepatocelular/diagnóstico , Carcinoma Hepatocelular/etiología , Procedimiento de Fontan/efectos adversos , Neoplasias Hepáticas/diagnóstico , Neoplasias Hepáticas/etiología , Carcinoma Hepatocelular/patología , Detección Precoz del Cáncer/métodos , Procedimiento de Fontan/métodos , Humanos , Hipertensión Portal/complicaciones , Hígado/diagnóstico por imagen , Neoplasias Hepáticas/patología , Masculino , Factores de Tiempo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA